Evidence map›Paper›PMID 27047475›Full record

ArticleFrontiers in microbiology2016

Identification and Partial Characterization of a Novel UDP-N-Acetylenolpyruvoylglucosamine Reductase/UDP-N-Acetylmuramate:l-Alanine Ligase Fusion Enzyme from Verrucomicrobium spinosum DSM 4136(T).

Kubra F Naqvi, Delphine Patin, Matthew S Wheatley, Michael A Savka, Renwick C J Dobson, Han Ming Gan, Hélène Barreteau, Didier Blanot, Dominique Mengin-Lecreulx, André O Hudson

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. iScience · 2025
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

Kubra F NaqviThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology Rochester, NY, USA.
Delphine PatinInstitute for Integrative Biology of the Cell, CEA, CNRS, Univ Paris-Sud, Université Paris-Saclay Orsay, France.
Matthew S WheatleyThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology Rochester, NY, USA.
Michael A SavkaThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology Rochester, NY, USA.
Renwick C J DobsonBiomolecular Interaction Centre, School of Biological Sciences, University of CanterburyChristchurch, New Zealand; Department of Biochemistry and Molecular Biology, Bio21 Molecular and Biotechnology Institute, The University of MelbourneParkville, VIC, Australia.
Han Ming GanMonash University Malaysia Genomics Facility, Monash University MalaysiaSelangor, Malaysia; School of Science, Monash University MalaysiaSelangor, Malaysia.
Hélène BarreteauInstitute for Integrative Biology of the Cell, CEA, CNRS, Univ Paris-Sud, Université Paris-Saclay Orsay, France.
Didier BlanotInstitute for Integrative Biology of the Cell, CEA, CNRS, Univ Paris-Sud, Université Paris-Saclay Orsay, France.
Dominique Mengin-LecreulxInstitute for Integrative Biology of the Cell, CEA, CNRS, Univ Paris-Sud, Université Paris-Saclay Orsay, France.
André O HudsonThomas H. Gosnell School of Life Sciences, Rochester Institute of Technology Rochester, NY, USA.
Rochester Institute of Technology · USCEA Paris-Saclay · FRMonash University Malaysia · MYUniversité Paris-Saclay · FRUniversity of Canterbury · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enzymes involved in synthesizing the bacterial cell wall are attractive targets for the design of antibacterial compounds, since this pathway is essential for bacteria and is absent in animals, particularly humans. A survey of the genome of a bacterium that belongs to the phylum Verrucomicrobia, the closest free-living relative to bacteria from the Chlamydiales phylum, shows genetic evidence that Verrucomicrobium spinosum possesses a novel fusion open reading frame (ORF) annotated by the locus tag (VspiD_010100018130). The ORF, which is predicted to encode the enzymes UDP-N-acetylenolpyruvoylglucosamine reductase (MurB) and UDP-N-acetylmuramate:l-alanine ligase (MurC) that are involved in the cytoplasmic steps of peptidoglycan biosynthesis, was cloned. In vivo analyses using functional complementation showed that the fusion gene was able to complement Escherichia coli murB and murC temperature sensitive mutants. The purified recombinant fusion enzyme (MurB/C Vs ) was shown to be endowed with UDP-N-acetylmuramate:l-alanine ligase activity. In vitro analyses demonstrated that the latter enzyme had a pH optimum of 9.0, a magnesium optimum of 10 mM and a temperature optimum of 44-46°C. Its apparent K m values for ATP, UDP-MurNAc, and l-alanine were 470, 90, and 25 μM, respectively. However, all attempts to demonstrate an in vitro UDP-N-acetylenolpyruvoylglucosamine reductase (MurB) activity were unsuccessful. Lastly, Hidden Markov Model-based similarity search and phylogenetic analysis revealed that this fusion enzyme could only be identified in specific lineages within the Verrucomicrobia phylum.

Indexed as

bacterial cell wallfusion enzymeMurBMurCpeptidoglycanUDP-N-acetylenolpyruvoylglucosamine reductaseUDP-N-acetylmuramate:l-alanine ligaseVerrucomicrobium spinosum

Identifiers

PMID27047475
PMCPMC4803751
OpenAlexW2332298005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.